GRFS (Grifols) Beginning Cash Position: $954 Mil (As of Mar. 2026)


GRFS Grifols SA GRFS
82 GF Score
Price $7.16
GF Value $8.71
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Grifols Beginning Cash Position?

Grifols GRFS +1.06% 82 Beginning Cash Position is $954 Mil as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 82/100 and a GF Value™ of $8.71 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Grifols's Beginning Cash Position for the quarter that ended in Mar. 2026 was $954 Mil.

Grifols's quarterly Beginning Cash Position increased from Sep. 2025 ($656 Mil) to Dec. 2025 ($727 Mil) and increased from Dec. 2025 ($727 Mil) to Mar. 2026 ($954 Mil).

Grifols's annual Beginning Cash Position declined from Dec. 2023 ($599 Mil) to Dec. 2024 ($554 Mil) but then increased from Dec. 2024 ($554 Mil) to Dec. 2025 ($1,148 Mil).

Grifols Beginning Cash Position Related Terms

Grifols Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Grifols's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Beginning Cash Position Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 654.97 2,834.86 598.69 553.93 1,147.54

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,059.46 868.26 655.74 727.38 953.76
GRFS
82GF Score
Grifols SA GRFS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $954 Mil mean?
Grifols (GRFS) has a Beginning Cash Position of $954 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Grifols and its competitors.
Is Grifols' Beginning Cash Position too high?
Grifols' current Beginning Cash Position is $954 Mil. Overall, Grifols has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Beginning Cash Position compare to LLY and JNJ?
Grifols' Beginning Cash Position of $954 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Grifols and its competitors. Grifols's current Beginning Cash Position is $954 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.71, compared to a current price of $7.16 — trading 17.8% below its estimated fair value. The current Beginning Cash Position is $954 Mil. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Grifols (GRFS), the current Beginning Cash Position is $954 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.16 is trading 17.8% below its estimated GF Value™ of $8.71. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Beginning Cash Position: $954 Mil
  • GF Value™: $8.71 vs. price of $7.16 (17.8% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score

Get the complete analysis for GRFS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.16
Price
$8.71
GF Value